v3.25.2
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Total revenues   $ 2,342   $ 119,371
Cost of revenues   (2,342)   (119,371)
Operating expenses:        
Research and development $ 1,677,014 501,158 $ 3,618,694 1,596,198
General and administrative 1,086,865 1,243,517 2,171,693 2,265,568
Total operating expenses 2,763,879 1,744,675 5,790,387 3,861,766
Loss from operations (2,763,879) (1,744,675) (5,790,387) (3,861,766)
Other income (expense):        
Foreign currency transaction (loss) gain (8,045) 473 (8,833) 1,682
Interest income, net 69,823 35,925 145,851 64,767
Research and development incentives   (31,819)   (25,488)
Other income 125 43 125 43
Change in fair value of convertible debt   95,551   260,933
Total other income 61,903 100,173 137,143 301,937
Net loss applicable to common stockholders $ (2,701,976) $ (1,644,502) $ (5,653,244) $ (3,559,829)
Basic net loss per share (in Dollars per share) $ (0.82) $ (1.31) $ (1.79) $ (3.71)
Diluted net loss per share (in Dollars per share) $ (0.82) $ (1.31) $ (1.79) $ (3.71)
Basic weighted average common shares outstanding (in Shares) 3,278,677 1,258,985 3,164,784 958,341
Diluted weighted average common shares outstanding (in Shares) 3,278,677 1,258,985 3,164,784 958,341
Grant revenue        
Total revenues   $ 2,342   $ 119,371